ArticleMolecular cancer therapeutics2011

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Majid Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.